Outlook Therapeutics develops ONS-5010/LYTENAVA, an eye treatment based on bevacizumab for wet macular degeneration. OTLK reports earnings on Fri, Dec 18, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 11 | Ascendiant Capital | Target raised | Buy | |
| Jul 27 | HC Wainwright & Co. | Maintained | Hold | |
| Jul 27 | BTIG | Upgrade | Buy | |
| Jun 11 | Ascendiant Capital | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in OTLK in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OTLK is in one of them and how their past OTLK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OTLK in an article yet. Here's the latest on the wider market.
About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company based in Iselin, New Jersey. Its main product is ONS-5010/LYTENAVA, an eye treatment based on bevacizumab, an antibody first approved for cancer and adapted for use in the eye. It is used to treat wet macular degeneration, a condition that can damage central vision. The product is approved in the European Union and the United Kingdom, where the company sells it directly, and it is under review in the United States.
- Headquarters
- Iselin, NJ